Gigamon Extends the Deep Observability Pipeline for AI-Enabled Network and Security Operations with New GigaSMART Network Appliance Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc. (“Oncotelic” or the…
TOWER ONE WIRELESS ANNOUNCES TWENTY- SIX TOWERS COMPLETED – ADDITIONAL NON-CANCELLABLE RENT OF $2,600,000
TOWER ONE CONSTRUCTION UPDATE FOR THE MONTH OF AUGUST 2022 VANCOUVER, BC, CANADA , Sept….
Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical’s Rencofilstat to Treat Alcohol-Related Liver Disease
EDISON, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage…
Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics
All Merger-related proposals approved at the Annual Meeting of Stockholders BASKING RIDGE, N.J., Sept. 14,…
eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
– Dose escalation based on positive recommendation from independent data safety monitoring board after safety…
Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014
TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB:…
TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS
SAN DIEGO, Sept. 14, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical…
Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of Directors
CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage…
Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration
LUNA Phase 2 Study in Wet AMD – Study Design Objective: The LUNA trial is…
Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis
European Commission expected to issue its decision on orphan designation in approximately 30 days BASKING…
CymaBay Therapeutics Hosting Virtual Analyst Day on September 22
Redefining Expectations for PBC Patients September 22, 2022 at 10:30 AM ET NEWARK, Calif., Sept….
SOTIO Bolsters Leadership Team with Appointment of Martin Steegmaier as Chief Scientific Officer
PRAGUE, Czech Republic, Sept. 14, 2022 (GLOBE NEWSWIRE) — SOTIO Biotech, a clinical stage immuno-oncology…
Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
Encouraging Phase II data supports broad therapeutic potential of eftilagimod alpha in non-small cell lung…
SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
Wellution™ offers dozens of products including natural supplements, creams, gels and hemp-based products on Amazon.com…
Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting
– New preclinical data indicate IL-27 induces a gene expression signature that has been associated with…
Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference
SAN DIEGO and TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or…
ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
ASLAN plans to begin TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) in the…
Larimar Therapeutics Announces $70 Million Underwritten Offering
BALA CYNWYD, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar” or the…
Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients
Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected…
Oxford Biomedica Solutions signs agreement with new partner to deliver The Full Solution for their AAV programs
Oxford Biomedica Solutions signs agreement with new partner to deliver The Full Solution for their…